Trial record 2 of 6 for:
anteris technologies
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study (DurAVR™ EFS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05712161 |
Recruitment Status :
Active, not recruiting
First Posted : February 3, 2023
Last Update Posted : January 31, 2024
|
Sponsor:
Anteris Technologies Ltd.
Information provided by (Responsible Party):
Anteris Technologies Ltd.
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | January 13, 2023 | ||||||
First Posted Date ICMJE | February 3, 2023 | ||||||
Last Update Posted Date | January 31, 2024 | ||||||
Actual Study Start Date ICMJE | August 7, 2023 | ||||||
Actual Primary Completion Date | December 29, 2023 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures |
|
||||||
Original Other Pre-specified Outcome Measures | Same as current | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study | ||||||
Official Title ICMJE | Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study | ||||||
Brief Summary | To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis. | ||||||
Detailed Description | The primary objective is to assess the acute and long-term safety and feasibility of the DurAVR™ device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement as assessed by the Heart Team at the enrolling institutions. This is a prospective, non-randomized, single-arm, multi-center Study. Subjects will be consented for follow-up to 10 years. |
||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Not Applicable | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: A prospective, non-randomized, single-arm, multi-center study Masking: None (Open Label)Primary Purpose: Device Feasibility |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE | Device: DurAVRTM THV System
The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
|
||||||
Study Arms ICMJE | Experimental: DurAVR™ THV System
TAVR procedure
Intervention: Device: DurAVRTM THV System
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Active, not recruiting | ||||||
Estimated Enrollment ICMJE |
15 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | December 2033 | ||||||
Actual Primary Completion Date | December 29, 2023 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
Anatomical
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 65 Years and older (Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT05712161 | ||||||
Other Study ID Numbers ICMJE | SP0028 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Current Responsible Party | Anteris Technologies Ltd. | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | Anteris Technologies Ltd. | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
|
||||||
PRS Account | Anteris Technologies Ltd. | ||||||
Verification Date | January 2024 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |